uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Robert Gut sold 3,336 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the transaction, the director now owns 56,879 shares of the company's stock, valued at approximately $821,901.55. The trade was a 5.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
uniQure Stock Performance
QURE traded up $0.27 during mid-day trading on Tuesday, reaching $14.22. 852,314 shares of the stock were exchanged, compared to its average volume of 1,953,833. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The company has a 50 day moving average price of $14.29 and a two-hundred day moving average price of $13.99. uniQure N.V. has a 1 year low of $3.73 and a 1 year high of $19.18.
uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. Equities analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.
Analyst Ratings Changes
Several research analysts have issued reports on QURE shares. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital reissued a "buy" rating and set a $38.00 target price on shares of uniQure in a research note on Friday, May 30th. Finally, Guggenheim reissued a "buy" rating and set a $28.00 target price on shares of uniQure in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.
Check Out Our Latest Stock Analysis on uniQure
Hedge Funds Weigh In On uniQure
A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Twin Tree Management LP purchased a new position in shares of uniQure in the 4th quarter worth about $77,000. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure in the 1st quarter worth about $106,000. OMERS ADMINISTRATION Corp purchased a new position in shares of uniQure in the 1st quarter worth about $152,000. ADAR1 Capital Management LLC purchased a new stake in uniQure during the fourth quarter valued at about $177,000. Finally, Wells Fargo & Company MN lifted its holdings in uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
